...
首页> 外文期刊>Cell death & disease. >The pancreatitis-associated protein VMP1, a key regulator of inducible autophagy, promotes KrasG12D-mediated pancreatic cancer initiation
【24h】

The pancreatitis-associated protein VMP1, a key regulator of inducible autophagy, promotes KrasG12D-mediated pancreatic cancer initiation

机译:胰腺炎相关蛋白VMP1是诱导型自噬的关键调节因子,可促进Kras G12D 介导的胰腺癌的发生

获取原文
           

摘要

Both clinical and experimental evidence have firmly established that chronic pancreatitis, in particular in the context of Kras oncogenic mutations, predisposes to pancreatic ductal adenocarcinoma (PDAC). However, the repertoire of molecular mediators of pancreatitis involved in Kras-mediated initiation of pancreatic carcinogenesis remains to be fully defined. In this study we demonstrate a novel role for vacuole membrane protein 1 (VMP1), a pancreatitis-associated protein critical for inducible autophagy, in the regulation of Kras-induced PDAC initiation. Using a newly developed genetically engineered model, we demonstrate that VMP1 increases the ability of Kras to give rise to preneoplastic lesions, pancreatic intraepithelial neoplasias (PanINs). This promoting effect of VMP1 on PanIN formation is due, at least in part, by an increase in cell proliferation combined with a decrease in apoptosis. Using chloroquine, an inhibitor of autophagy, we show that this drug antagonizes the effect of VMP1 on PanIN formation. Thus, we conclude that VMP1-mediated autophagy cooperate with Kras to promote PDAC initiation. These findings are of significant medical relevance, molecules targeting autophagy are currently being tested along chemotherapeutic agents to treat PDAC and other tumors in human trials.
机译:临床和实验证据均已确定慢性胰腺炎,特别是在Kras致癌突变的情况下,易患胰腺导管腺癌(PDAC)。但是,涉及Kras介导的胰腺癌发生的胰腺炎分子介导物库仍待充分定义。在这项研究中,我们证明液泡膜蛋白1(VMP1)是胰腺炎相关蛋白,对诱导型自噬至关重要,在调节Kras诱导的PDAC起始中起着新作用。使用新开发的基因工程模型,我们证明VMP1增加了Kras引起肿瘤前病变,胰腺上皮内瘤样变(PanINs)的能力。 VMP1对PanIN形成的这种促进作用至少部分是由于细胞增殖增加和凋亡减少所致。使用氯喹,自噬的抑制剂,我们表明,这种药物拮抗VMP1对PanIN形成的影响。因此,我们得出结论,VMP1介导的自噬与Kras协同促进PDAC的启动。这些发现具有重大医学意义,目前正在人类试验中将靶向自噬的分子与化学治疗剂一起测试以治疗PDAC和其他肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号